Drug Approval | December 20, 2023
Briefs: Aurobindo Pharma and Granules Pharmaceuticals
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Both the India and GCC entities will be operated by separate dedicated management teams
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated
